Steglujan Tablet, Film Coated
Product Images NDC 0006-5368

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Steglujan (NDC 0006-5368). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Steglujan 01)

Chemical structure of ertugliflozin and sitagliptin, the active ingredients in STEGLUJAN tablets. The diagram shows the molecular arrangement and connectivity of atoms in these compounds.*

FDA Label Image

Chemical Structure (Steglujan 02)

Chemical structure depicting ertugliflozin and sitagliptin, the active ingredients in STEGLUJAN, shown with phosphate and water molecules (H3PO4 and H2O). This image illustrates the molecular arrangement of these compounds as part of the pharmaceutical product's labeling data.*

FDA Label Image

Figure 1 (Steglujan 03)

A horizontal dot-and-whisker plot showing geometric mean ratios with 90% confidence intervals for AUC and Cmax of different drugs relative to ertugliflozin alone, including sitagliptin 100 mg, metformin 1000 mg, glimepiride 1 mg, simvastatin 40 mg, and rifampin 600 mg. The graph compares pharmacokinetic parameters expressed as percentages, with ertugliflozin doses standardized to 15 mg single dose.*

FDA Label Image

Figure 2 (Steglujan 04)

A forest plot chart depicting the geometric mean ratio with 90% confidence intervals for the AUC and Cmax of various single-dose medications (Sitagliptin 100 mg, Metformin 1000 mg, Glimepiride 1 mg, Simvastatin 40 mg, and Simvastatin Acid) relative to coadministration with ertugliflozin, which was administered as a 15 mg single dose. The x-axis represents the relative ratio to concomitant medication alone (%).*

FDA Label Image

Figure 3 (Steglujan 05)

A line graph showing percent mean change from baseline in HbA1c levels over 26 weeks for STEGLUJAN (ertugliflozin and sitagliptin) treatment groups. The graph compares four groups: Ertu 5 mg, Ertu 15 mg, Sita 100 mg, and their combinations across weeks 6, 12, 18, and 26 with sample sizes indicated below. The chart illustrates the time course of HbA1c reduction by treatment.*

FDA Label Image

Principal Display Panel (5 mg/100 mg Tablet Bottle Label)

Label for STEGLUJAN tablets, film coated, containing ertugliflozin and sitagliptin at a strength of 5 mg / 100 mg. The label indicates a package of 30 tablets, prescription use only, and includes storage instructions. The labeler is Merck Sharp & Dohme LLC. The label features the product name, active ingredients, dosage strength, barcodes, and manufacturer details.*

FDA Label Image

Principal Display Panel (15 mg/100 mg Tablet Bottle Label)

The image shows a Steglujan 15 mg / 100 mg tablet label containing ertugliflozin and sitagliptin oral film-coated tablets. The label includes the tablet strength, a barcode, the Merck logo, NDC 0006-5368-03, and specifies a package size of 30 tablets. It also notes the drug is prescription only and includes an area reserved for 2D serialization barcode, serial number, expiry, and lot information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.